Sun Pharma Advanced Research Company Ltd - 532872 - Statutory Auditors Certificate In Terms Of Regulation 169(5) Of SEBI ICDRA Regulations, 2018
Sun Pharma Advanced Research Co confirmed the receipt of Rs. 149.99 crore for a preferential allotment of 3.85 crore convertible warrants. This capital infusion strengthens the company's financial position.
May 25 2026 20:55:39
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research confirmed receiving Rs. 149.99 crore for the preferential allotment of 3.85 crore warrants to Shanghvi Finance. The statutory auditor certified compliance with SEBI ICDR Regulations.
May 25 2026 20:39:21
Sun Pharma Advanced Research Company Ltd - 532872 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Sun Pharma Advanced Research Co's promoter group, including Shanghvi Finance Private Ltd and Persons Acting in Concert, increased their fully diluted shareholding to 69.31% by acquiring 3.85 crore warrants through a preferential allotment. These warrants, convertible into equity shares at Rs.155.80 each, signify a substantial investment by the promoter.
May 20 2026 17:18:52
Sun Pharma Advanced Research Company Ltd - 532872 - Update On PDP-716 NDA
Sun Pharma Advanced Research's licensing partner Ocuvex Therapeutics Inc. received a Complete Response Letter (CRL) from the U.S. FDA for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility, causing a delay in potential market approval.
May 19 2026 18:47:59
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research's licensing partner, Ocuvex Therapeutics, received a Complete Response Letter (CRL) from the U.S. FDA for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility.
May 19 2026 18:45:27
Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Allotment
Sun Pharma Advanced Research Co (SPARC) has allotted 3.85 crore warrants on a preferential basis to Shanghvi Finance Private Limited at an issue price of INR 155.80 per warrant. The company has received INR 149.99 crore, representing 25% of the total warrant issue price. Each warrant is convertible into one equity share.
May 19 2026 12:42:23
Sun Pharma Advanced Research Company Ltd - 532872 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026
Sun Pharma Advanced Research Co board will convene on May 18, 2026, to consider and approve its Q4 FY26 and full-year FY26 financial results. This meeting will finalize the company's financial performance for the period ending March 31, 2026.
May 11 2026 19:05:38
Read More